cetirizine and Erythema
cetirizine has been researched along with Erythema in 18 studies
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.
cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here we studied the development of erythema after histamine iontophoresis in 12 AE patients and 12 healthy volunteers by means of a RGB-camera for recording true colour images." | 5.08 | Flare responses of atopic eczema patients analysed with true colour images. ( Forster, C; Handwerker, HO; Heyer, G; Nischik, M; Rukwied, R, 1997) |
| " The areas of weal and flare induced by intracutaneous injections of histamine were measured using planimetry, weal thickness by A-scan pulsed ultrasound and erythema index by a device which measures the relative reflectance of red and green light." | 5.07 | Effects of cetirizine, loratadine and terfenadine on histamine weal and flare reactions. ( Hill, S; Lever, LR; Marks, R; Rosenberg, R; Thompson, D, 1992) |
| " We herein describe a case of a 13year old male patient with left thalamic mixed germ cell tumour treated by multimodality approach, who developed flagellate erythema after two cycles of combination chemotherapy with bleomycin, etoposide and cisplatin (BEP)." | 3.83 | Bleomycin induced flagellate erythema in a patient with thalamic mixed germ cell tumour: Report of a rare adverse effect. ( Biswas, A; Julka, PK, 2016) |
| "Acute skin inflammation occurs following topical aminolevulinic acid-photodynamic therapy (ALA-PDT), but its nature and mediation are ill defined." | 3.73 | Histamine is released following aminolevulinic acid-photodynamic therapy of human skin and mediates an aminolevulinic acid dose-related immediate inflammatory response. ( Brooke, RC; Church, MK; Clough, GF; Friedmann, PS; Rhodes, LE; Sidhu, MK; Sinha, A; Watson, RE, 2006) |
| " The objective of this study was to evaluate the impact of antihistamines upon adverse effects following ALA-PDT." | 2.84 | A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy. ( Goldman, MP; Jones, IT; Vanaman Wilson, MJ; Wu, DC, 2017) |
| "Levocetirizine was used as a comparator." | 2.71 | Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. ( Boutsiouki, P; Church, MK; Clough, GF; Denham, KJ, 2003) |
| "Two double-blind clinical pharmacology studies were performed in healthy volunteers to compare the dermal pharmacodynamic profile of epinastine with cetirizine, a well-documented anti-H1 antagonist, after oral administration at the usual recommended dosage, i." | 2.70 | Dermal objective pharmacodynamic profile of cetirizine and epinastine: two controlled, randomised, double-blind, crossover studies. ( Leroy, T; van Neste, D, 2002) |
| "In contrast, controls reported a burning pain after the injection of ACh, whereas AE patients felt predominantly pruritus." | 2.69 | Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients. ( Heyer, G; Rukwied, R, 1999) |
Research
Studies (18)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 7 (38.89) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Vargas-Mora, P | 1 |
| Arceu, M | 1 |
| Cortés, A | 1 |
| Carreño, L | 1 |
| Vanaman Wilson, MJ | 1 |
| Jones, IT | 1 |
| Wu, DC | 1 |
| Goldman, MP | 1 |
| Veraldi, S | 1 |
| Pontini, P | 1 |
| Nazzaro, G | 1 |
| Biswas, A | 1 |
| Julka, PK | 1 |
| Bäumer, W | 1 |
| Stahl, J | 1 |
| Sander, K | 1 |
| Petersen, LJ | 1 |
| Paps, J | 1 |
| Stark, H | 1 |
| Kietzmann, M | 1 |
| Olivry, T | 1 |
| Inamadar, AC | 1 |
| Palit, A | 1 |
| Athanikar, SB | 1 |
| Sampagavi, VV | 1 |
| Deshmukh, NS | 1 |
| Leroy, T | 1 |
| van Neste, D | 3 |
| Denham, KJ | 1 |
| Boutsiouki, P | 1 |
| Clough, GF | 2 |
| Church, MK | 2 |
| Brooke, RC | 1 |
| Sinha, A | 1 |
| Sidhu, MK | 1 |
| Watson, RE | 1 |
| Friedmann, PS | 1 |
| Rhodes, LE | 1 |
| de la Cuadra, J | 1 |
| Teruel, M | 1 |
| Teixidó, P | 1 |
| Roma, J | 1 |
| Hannuksela, M | 1 |
| Kalimo, K | 1 |
| Lammintausta, K | 1 |
| Mattila, T | 1 |
| Turjanmaa, K | 1 |
| Varjonen, E | 1 |
| Coulie, PJ | 1 |
| Leroy, DT | 1 |
| de Brouwer, B | 1 |
| Rihoux, JP | 2 |
| Rukwied, R | 2 |
| Nischik, M | 1 |
| Forster, C | 1 |
| Heyer, G | 2 |
| Handwerker, HO | 1 |
| Nissen, JB | 1 |
| Egekvist, H | 1 |
| Bjerring, P | 1 |
| Kragballe, K | 1 |
| Kränke, B | 1 |
| Kern, T | 1 |
| Lever, LR | 1 |
| Hill, S | 1 |
| Marks, R | 1 |
| Rosenberg, R | 1 |
| Thompson, D | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy[NCT02451579] | 20 participants (Anticipated) | Interventional | 2015-02-28 | Completed | |||
| Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study[NCT00884325] | Phase 4 | 40 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Dermatology Life Quality Index (DLQI) Questionnaire Scores at Baseline, Week 2 and Week 4
Consented subjects who met inclusion/exclusion criteria were asked to complete a DLQI (Dermatology Life Quality Index)at Baseline, Week 2 and Week 4. The DLQI is a 10 item questionnaire broken down into 6 domains; symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment with a total score ranging from 0-30 (no effect on subject's life for 0, extremely large effect on subject's life for 30) (NCT00884325)
Timeframe: Baseline - Week 2 - Week 4
| Intervention | units on a scale (Median) | ||
|---|---|---|---|
| DLQI - Baseline | DLQI - Week 2 | DLQI - Week 4 | |
| Subjects Receiving Placebo | 8.00 | 5.5 | 4.00 |
| Subjects Receiving Xyzal | 7.5 | 3.5 | 2.00 |
Pruritus VAS Scores at Baseline, Week 2 and Week 4
Consented subjects who met inclusion/exclusion criteria were assigned either 5mg levocetirizine dihydrochloride (Xyzal) or placebo to be taken daily each evening for 28 days. Subjects were asked to complete a Visual Analog Scale to measure itch at Baseline, Week 2 and Week 4. The scale is an eleven point scale ranging from 0-10 with 0 indicating no itch to 10 indicating itch that frequently interferes with daily activities. (NCT00884325)
Timeframe: Baseline - Week 2-Week 4
| Intervention | units on a scale (Median) | ||
|---|---|---|---|
| Baseline | Week 2 | Week 4 | |
| Subjects Receiving Placebo | 7.5 | 5.9 | 6.4 |
| Subjects Receiving Xyzal | 7.8 | 6.10 | 4.15 |
Trials
11 trials available for cetirizine and Erythema
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Cetirizine; Double-Blind Method; Drug Eruption | 2017 |
Dermal objective pharmacodynamic profile of cetirizine and epinastine: two controlled, randomised, double-blind, crossover studies.
Topics: Administration, Oral; Adult; Cetirizine; Cross-Over Studies; Dibenzazepines; Double-Blind Method; Dr | 2002 |
Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin.
Topics: Adult; Anti-Allergic Agents; Cetirizine; Cross-Over Studies; Double-Blind Method; Erythema; Histamin | 2003 |
Assessment of the wheal size and skin blood flow of the erythema induced by histamine and its modification with cetirizine and ebastine: a crossover, double-blind study.
Topics: Adolescent; Adult; Butyrophenones; Cetirizine; Double-Blind Method; Erythema; Female; Histamine; His | 1994 |
Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults.
Topics: Administration, Topical; Adult; Alanine Transaminase; Cetirizine; Dermatitis, Atopic; Dose-Response | 1993 |
Histamine-induced skin reactions using iontophoresis and H1-blockade.
Topics: Adult; Cetirizine; Cross-Over Studies; Double-Blind Method; Erythema; Female; Histamine; Histamine H | 1996 |
Flare responses of atopic eczema patients analysed with true colour images.
Topics: Adult; Cetirizine; Cross-Over Studies; Dermatitis, Atopic; Double-Blind Method; Erythema; Female; Hi | 1997 |
Effect of intradermal injection of methionine-enkephalin on human skin.
Topics: Adult; Anti-Allergic Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; CD3 Complex; C | 1999 |
Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients.
Topics: Acetylcholine; Adult; Cetirizine; Cholinergic Agents; Cross-Over Studies; Dermatitis, Atopic; Double | 1999 |
Effects of cetirizine, loratadine and terfenadine on histamine weal and flare reactions.
Topics: Administration, Oral; Adult; Cetirizine; Cyproheptadine; Double-Blind Method; Erythema; Female; Hist | 1992 |
Inhibition of the cutaneous response to histamine by H1-blocking agents. Quantitative evaluation of microvascular changes in the skin after histamine challenge and a comparison of the effects of a single intake of cetirizine and terfenadine.
Topics: Adult; Benzhydryl Compounds; Cetirizine; Dermatitis; Double-Blind Method; Erythema; Female; Histamin | 1988 |
Other Studies
7 other studies available for cetirizine and Erythema
| Article | Year |
|---|---|
Multiple annular plaques in an adult woman.
Topics: Cetirizine; Dapsone; Eosinophilia; Erythema; Female; Humans; Hydroxychloroquine; Middle Aged; Predni | 2020 |
An Erythematous-squamous Lesion of the Foot: A Quiz.
Topics: Cetirizine; Erythema; Foot Dermatoses; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Pityria | 2018 |
Bleomycin induced flagellate erythema in a patient with thalamic mixed germ cell tumour: Report of a rare adverse effect.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Betamethaso | 2016 |
Lack of preventing effect of systemically and topically administered histamine H(1) or H(4) receptor antagonists in a dog model of acute atopic dermatitis.
Topics: Aging; Animals; Antigens, Dermatophagoides; Cetirizine; Dermatitis, Atopic; Dermatophagoides farinae | 2011 |
Multiple fixed drug eruptions due to cetirizine.
Topics: Cetirizine; Drug Eruptions; Erythema; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Middle A | 2002 |
Histamine is released following aminolevulinic acid-photodynamic therapy of human skin and mediates an aminolevulinic acid dose-related immediate inflammatory response.
Topics: Adult; Aged; Aminolevulinic Acid; Cetirizine; Dose-Response Relationship, Drug; Erythema; Female; Hi | 2006 |
Multilocalized fixed drug eruption to the antihistamine cetirizine.
Topics: Adult; Cetirizine; Drug Eruptions; Erythema; Histamine H1 Antagonists; Humans; Male; Skin | 2000 |